Abstract: Systems and methods for calibrating an onboard vehicle scale may include disposing a vehicle upon a reference scale; determining reference weight information corresponding to a weight of at least a portion of the vehicle using the reference scale; automatically and wirelessly communicating the reference weight information to an onboard scale coupled to the vehicle; and automatically calibrating the onboard scale using the reference weight information.

Abstract: Systems and methods for calibrating an onboard vehicle scale may include disposing a vehicle upon a reference scale; determining reference weight information corresponding to a weight of at least a portion of the vehicle using the reference scale; automatically and wirelessly communicating the reference weight information to an onboard scale coupled to the vehicle; and automatically calibrating the onboard scale using the reference weight information.

Abstract: Systems and methods for calibrating an onboard vehicle scale may include disposing a vehicle upon a reference scale; determining reference weight information corresponding to a weight of at least a portion of the vehicle using the reference scale; automatically and wirelessly communicating the reference weight information to an onboard scale coupled to the vehicle; and automatically calibrating the onboard scale using the reference weight information.

Abstract: Systems and methods for calibrating an onboard vehicle scale may include disposing a vehicle upon a reference scale; determining reference weight information corresponding to a weight of at least a portion of the vehicle using the reference scale; automatically and wirelessly communicating the reference weight information to an onboard scale coupled to the vehicle; and automatically calibrating the onboard scale using the reference weight information.

Abstract: Systems and methods for calibrating an onboard vehicle scale may include disposing a vehicle upon a reference scale; determining reference weight information corresponding to a weight of at least a portion of the vehicle using the reference scale; automatically and wirelessly communicating the reference weight information to an onboard scale coupled to the vehicle; and automatically calibrating the onboard scale using the reference weight information.

Abstract: Devices and methods of measuring a loaded weight of a vehicle are disclosed. The device may include a sensor assembly configured to detect pressure in the at least one air spring. The device may additionally include a solenoid valve assembly disposed between the sensor assembly and the at least one air spring and configured, when the sensor assembly is not detecting the pressure, to isolate the sensor assembly from the pressure in the at least one air spring while not isolating the at least one air spring from the pressure source. The device may further include a processor assembly configured to calculate a loaded weight of the vehicle based on the detected pressure, and a display assembly configured to display the calculated loaded weight.

Abstract: The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

Abstract: The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

Abstract: The invention relates to a method of treating fibromyalgia and other disorders in a mammal by administering a compound compound of Formula I R1 is straight or branched unsubstituted alkyl of from 1 to 5 carbon atoms, unsubstituted phenyl, or unsubstituted cycloalkyl of from 3 to 6 carbon atoms; R2 is hydrogen or methyl; and R3 is hydrogen, methyl, or carboxyl, or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

Abstract: The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

Abstract: The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

Abstract: This invention relates to a method of treating a disorder selected from OCD, agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, PTSD, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia by administering a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl; and R2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The invention also relates to a method of treating the above disorders by administering the compound (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid.

Abstract: This invention relates to certain ?-amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.

Abstract: The invention is a novel series of cyclic amino acids which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as well as methods of preparing the compounds and novel intermediates useful in the preparation of the final compounds are included.

Abstract: Certain ?-amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel are disclosed. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.

Abstract: This invention relates to prodrugs of certain amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.

Abstract: This invention relates to novel tetrazole and oxadiazalone ?-amino acids derivatives of the formula wherein G is wherein R1 through R4 are defined as in the specification, pharmaceutical compositions containing them and their use for the treatment of various central nervous system and other disorders. The cyclopropyl ?-amino acids derivatives of this invention exhibit activity as alpha2delta ligands (?2? ligands). Such compounds have affinity for the ?2? subunit of a calcium channel.